BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Li N, Zhu QX, Li GZ, Wang T, Zhou H. Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1α and inhibiting the RhoA/ROCK pathway. World J Diabetes 2023; 14(12): 1862-1876 [PMID: 38222788 DOI: 10.4239/wjd.v14.i12.1862]
URL: https://www.wjgnet.com/1948-9358/full/v14/i12/1862.htm
(136) (147) (0) (0) (3) (5756) (24)
Number Citing Articles
1
Loredana N. Ionică, Adina V. Lința, Alina D. Bătrîn, Iasmina M. Hâncu, Bogdan M. Lolescu, Maria D. Dănilă, Lucian Petrescu, Ioana M. Mozoș, Adrian Sturza, Danina M. Muntean. The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview. International Journal of Molecular Sciences 2024; 25(14) doi: 10.3390/ijms25147711
2
Yifeng Gao, En Li, Fang Li, Ying Cui, Qi Shu, Yan Zhang, Lijuan Kong, Han Li, Xiaoyu Yang. Dapagliflozin alleviates mitochondrial damage in the myocardium under diabetic conditions by targeting sortilin. Cellular and Molecular Life Sciences 2025; 82(1) doi: 10.1007/s00018-025-05793-8
3
Qiang Fan, Yabo Wang, Qi An, Yunfei Ling. Right ventricular dysfunction following surgical repair of tetralogy of Fallot: Molecular pathways and therapeutic prospects. Biomedicine & Pharmacotherapy 2025; 184 doi: 10.1016/j.biopha.2025.117924
4
Teodora Mateoc, Andrei-Luca Dumitrascu, Corina Flangea, Daniela Puscasiu, Tania Vlad, Roxana Popescu, Cristina Marina, Daliborca-Cristina Vlad. SGLT2 Inhibitors: From Structure–Effect Relationship to Pharmacological Response. International Journal of Molecular Sciences 2025; 26(14) doi: 10.3390/ijms26146937
5
ANIS ISMAIL, GRACE ERNE, ALEXI VASBINDER, CHRISTINA G. HUTTEN, BAHJAT Z. GHAZZAL, IAN PIZZO, KRISTEN MACHADO DIAZ, TONIMARIE CLAIRE CATALAN, THERESA FARHAT, BRENNA KNOTT, PENNELOPE KUNKLE, MICHAEL SZAREK, MICHAEL J. DAVIES, PHILIPPE GABRIEL STEG, BERTRAM PITT, DEEPAK L. BHATT, SALIM S. HAYEK. Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients With Diabetes and Heart Failure: A SOLOIST-WHF Ancillary Study. Journal of Cardiac Failure 2026;  doi: 10.1016/j.cardfail.2026.01.018
6
Yanling Chen, Xun Liu, Yixuan Liu, Yujia Li, Dingxiang Li, Zhigang Mei, Yihui Deng. Mitochondrial quality control in diabetes mellitus and complications: molecular mechanisms and therapeutic strategies. Cell Death & Disease 2025; 16(1) doi: 10.1038/s41419-025-07936-y
7
Hang Su, Chun-qiang Zhang, Jiang-fei An, Yue-ting Tuo, Ting-ting Chen, Long Yang, Ling-yun Fu, Wen-bing Yao, Ling Tao, Yi-ni Xu, Xiang-chun Shen. CVB-D attenuates experimental diabetic cardiomyopathy by alleviating mitochondrial dysfunction via the JAK1-STAT1 signaling axis in vivo and in vitro. Chinese Medicine 2026; 21(1) doi: 10.1186/s13020-026-01411-2
8
Elina Khattab, Michaelia Kyriakou, Elena Leonidou, Stefanos Sokratous, Angeliki Mouzarou, Michael M. Myrianthefs, Nikolaos P. E. Kadoglou. Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives. Pharmaceuticals 2025; 18(1) doi: 10.3390/ph18010134
9
Jinyan Chen, Kexin Zhang, Xiao Yu, Jiayi Ren, Chengxia Kan, Sufang Sheng, Fang Han, Yang Zhang, Jian Chen, Xiaodong Sun. Flavonoids in Metabolic Disease: A Narrative Review of Mechanisms and Therapeutic Potential. Phytotherapy Research 2025; 39(11) doi: 10.1002/ptr.70107
10
Taoshan Feng, Meilian Liu, Dan Zhong, Xusan Xu, Zhengqiang Luo, Wensen Zhang, Yajun Wang, Riling Chen, Xiaoming Chen, Guoda Ma. Empagliflozin Ameliorates Diabetic Cardiomyopathy by Inhibiting Ferroptosis via SIRT3: Mechanisms and Therapeutic Implications. Antioxidants 2026; 15(5) doi: 10.3390/antiox15050543
11
Jianing Chen, Fengqi Wan, Kaiyue Wu, Xinling Xie, Tingting Wu. The mitochondrial protective mechanisms mediated by SGLT2i: from molecular basis to clinical implications. Xenobiotica 2026; 56(2) doi: 10.1080/00498254.2026.2613138
12
Mina Y. George, Mohamed S. Dabour, Eman Rashad, Beshay N. Zordoky. Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy. Antioxidants 2024; 13(6) doi: 10.3390/antiox13060671
13
Iacob-Daniel Goje, Valentin Laurențiu Ordodi, Greta-Ionela Goje, Florina Maria Bojin, Andrei-Dragoș Crăciun, Daniela Crîsnic, Mihnea Derban, Andreea Severina Barbulescu, Valentina Gabriela Ciobotaru, Virgil Păunescu, Daniel-Florin Lighezan. Empagliflozin Mitigates Doxorubicin-Induced Cardiotoxicity in Rats: Electrocardiographic, Biochemical, and Histopathological Evidence. International Journal of Molecular Sciences 2026; 27(7) doi: 10.3390/ijms27073090
14
Xinxin Liu, Yingqi Ma, Xuefeng Wang, Xiaowen Zhang, Chen Shen, Youzhu Su, Xing Chang, Hao Zhou, Jian-Ping Liu. Cross-regulatory mechanisms linking ferroptosis, epigenetics, and circadian rhythm to mitochondrial quality control in diabetic cardiomyopathy. Journal of Advanced Research 2026; 84 doi: 10.1016/j.jare.2025.09.046
15
Arwa Mithaiwala, Angel Godad. Exploring Hippo YAP/TAZ Signaling: A Novel Avenue for Cardiovascular Disorders. Cell Biology International 2025; 49(9) doi: 10.1002/cbin.70052
16
Elena Rykova, Elena Shmakova, Igor Damarov, Tatiana Merkulova, Julia Kzhyshkowska. Non-Coding RNA in Type 2 Diabetes Cardio–Renal Complications and SGLT2 Inhibitor Response. International Journal of Molecular Sciences 2025; 26(22) doi: 10.3390/ijms262211198
17
Fang Han, Jing-Wen Zhang, Xiao-Dong Sun, Cheng-Xia Kan, Ke-Xin Zhang. Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control. World Journal of Diabetes 2024; 15(2): 137-141 doi: 10.4239/wjd.v15.i2.137
18
Sachin Dhiman, Sanchit Dhankhar, Anjali Garg, Manni Rohilla, Monika Saini, Thakur Gurjeet Singh, Samrat Chauhan, Samy Selim, Soad K. Al Jaouni, Sabina Yasmin, Naseem Begum, Aziza Alshahrani, Mohammad Yousuf Ansari. Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy. Heliyon 2024; 10(21) doi: 10.1016/j.heliyon.2024.e39996
19
Nada A. Elbaik, Shimaa M. Elshazly, Atef El-Gharbawy, Mahmoud H. Elbatreek. Agomelatine and empagliflozin synergistically protect against diabetic cardiomyopathy via nrf2/HO-1 signaling. European Journal of Pharmacology 2025; 1005 doi: 10.1016/j.ejphar.2025.178054
20
Maja Muric, Ivan Srejovic, Jovana Novakovic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Marina Nikolic, Nevena Lazarevic, Marijana Andjic, Aleksandar Kocovic, Jovana Jakovljevic Uzelac, Sergey Bolevich, Vladimir Jakovljevic. The Combined Empagliflozin and Sacubitril/Valsartan Therapy Attenuates Isoproterenol-Induced Heart Failure in Rats: Functional, Molecular, and Structural Insights. Cardiovascular Drugs and Therapy 2026; 40(1) doi: 10.1007/s10557-025-07675-4
21
Remi Sato, Kosei Sakai, Satoshi Kameshima. Dapagliflozin inhibits TGF-β-induced transdifferentiation of valvular interstitial cells and mitral valvular degeneration. Journal of Molecular Medicine 2026; 104(1) doi: 10.1007/s00109-025-02615-z
22
Minghao Li, Ruiyi Zhang, Xinyuan Li, Hefeng Huang. The Metabolic Role of Mitochondria in the Perinatal Cardiac Development and Cardiovascular Diseases. Exploration 2026; 6(2) doi: 10.1002/EXP.20240414
23
Xiangling Duan, Xiaomeng Zhang, Bao Sun. The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications. Cardiovascular Diabetology 2025; 24(1) doi: 10.1186/s12933-025-02750-4
24
Betul Rabia Erdogan, Ebru Arioglu-Inan. SGLT2 inhibitors: how do they affect the cardiac cells. Molecular and Cellular Biochemistry 2025; 480(3) doi: 10.1007/s11010-024-05084-z
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.